Download MendeleyP(2) pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold
Nantermet, P.G., Burgey, C.S., Robinson, K.A., Pellicore, J.M., Newton, C.L., Deng, J.Z., Selnick, H.G., Lewis, S.D., Lucas, B.J., Krueger, J.A., Miller-Stein, C., White, R.B., Wong, B., McMasters, D.R., Wallace, A.A., Lynch Jr., J.J., Yan, Y., Chen, Z., Kuo, L., Gardell, S.J., Shafer, J.A., Vacca, J.P., Lyle, T.A.(2005) Bioorg Med Chem Lett 15: 2771-2775
- PubMed: 15911253
- DOI: https://doi.org/10.1016/j.bmcl.2005.03.110
- Primary Citation of Related Structures:
1Z71 - PubMed Abstract:
In this study, we have demonstrated that the critical hydrogen bonding motif of the established 3-aminopyrazinone thrombin inhibitors can be effectively mimicked by a 2-aminopyridine N-oxide. As this peptidomimetic core is more resistant toward oxidative metabolism, it also overcomes the metabolic liability associated with the pyrazinones. An optimization study of the P(1) benzylamide delivered the potent thrombin inhibitor 21 (K(i) = 3.2 nM, 2xaPTT = 360 nM), which exhibited good plasma levels and half-life after oral dosing in the dog (C(max) = 2.6 microM, t(1/2) = 4.5 h).
Organizational Affiliation:
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. philippe_nantermet@merck.com
